Qingfeng Zhu

Research output

Research output per year 2011 2019 2021 2024

• 41 Article
• 2 Comment/debate
• 1 Letter
• 1 Review article

Research output per year

Research output per year

Search results

• 2024

  Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial

  Roussos Torres, E. T., Ho, W. J., Danilova, L., Tandurella, J. A., Leatherman, J., Rafie, C., Wang, C., Brufsky, A., LoRusso, P., Chung, V., Yuan, Y., Downs, M., O’Connor, A., Shin, S. M., Hernandez, A., Engle, E. L., Piekarz, R., Streicher, H., Talebi, Z., Rudek, M., & 7 othersZhu, Q., Anders, R., Cimino-Mathews, A., Fertig, E., Jaffee, E. M., Stearns, V. & Connolly, R. M., 2024, (Accepted/In press) In: Nature Cancer.

  Research output: Contribution to journal › Article › peer-review

• Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances to tumor cells

  Wang, J., Gai, J., Zhang, T., Niu, N., Qi, H., Thomas, D. L., Li, K., Xia, T., Rodriguez, C., Parkinson, R., Durham, J., McPhaul, T., Narang, A. K., Anders, R. A., Osipov, A., Wang, H., He, J., Laheru, D. A., Herman, J. M., Lee, V., & 4 othersJaffee, E. M., Thompson, L., Zhu, Q. & Zheng, L., Feb 2024, In: Science Advances. 10, 6, eadk1827.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Radioimmunotherapy 100%
  • Pancreatic Neoplasms 68%
  • Radiosurgery 59%
  • T-Lymphocytes 44%
  • Antibodies 39%
• 2023

  A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma

  Heumann, T., Judkins, C., Li, K., Lim, S. J., Hoare, J., Parkinson, R., Cao, H., Zhang, T., Gai, J., Celiker, B., Zhu, Q., McPhaul, T., Durham, J., Purtell, K., Klein, R., Laheru, D., De Jesus-Acosta, A., Le, D. T., Narang, A., Anders, R., & 9 othersBurkhart, R., Burns, W., Soares, K., Wolfgang, C., Thompson, E., Jaffee, E., Wang, H., He, J. & Zheng, L., Dec 2023, In: Nature communications. 14, 1, 3650.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Adjuvant 100%
  • antibodies 95%
  • Nivolumab 94%
  • urelumab 77%
  • Agonist 77%

• Erratum: Uncovering the spatial landscape of molecular interactions within the tumor microenvironment through latent spaces (Cell Systems (2023) 14(4) (285–301.e4), (S2405471223000807), (10.1016/j.cels.2023.03.004))

  Deshpande, A., Loth, M., Sidiropoulos, D. N., Zhang, S., Yuan, L., Bell, A. T. F., Zhu, Q., Ho, W. J., Santa-Maria, C., Gilkes, D. M., Williams, S. R., Uytingco, C. R., Chew, J., Hartnett, A., Bent, Z. W., Favorov, S., Popel, A. S., Yarchoan, M., Kiemen, A., Wu, P. H., & 10 othersFujikura, K., Wirtz, D., Wood, L. D., Zheng, L., Jaffee, E. M., Anders, R. A., Danilova, L., Stein-O'Brien, G., Kagohara, L. T. & Fertig, E. J., Aug 16 2023, In: Cell Systems. 14, 8, p. 722 1 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access

  • Confusion 100%
  • Tumor Microenvironment 94%
  • Emotions 71%

• Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence

  Zhang, S., Yuan, L., Danilova, L., Mo, G., Zhu, Q., Deshpande, A., Bell, A. T. F., Elisseeff, J., Popel, A. S., Anders, R. A., Jaffee, E. M., Yarchoan, M., Fertig, E. J. & Kagohara, L. T., Dec 2023, In: Genome Medicine. 15, 1, 72.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • cabozantinib 100%
  • Nivolumab 84%
  • Spatial Analysis 79%
  • Hepatocellular Carcinoma 49%
  • Recurrence 35%

• Uncovering the spatial landscape of molecular interactions within the tumor microenvironment through latent spaces

  Deshpande, A., Loth, M., Sidiropoulos, D. N., Zhang, S., Yuan, L., Bell, A. T. F., Zhu, Q., Ho, W. J., Santa-Maria, C., Gilkes, D. M., Williams, S. R., Uytingco, C. R., Chew, J., Hartnett, A., Bent, Z. W., Favorov, S., Popel, A. S., Yarchoan, M., Kiemen, A., Wu, P. H., & 10 othersFujikura, K., Wirtz, D., Wood, L. D., Zheng, L., Jaffee, E. M., Anders, R. A., Danilova, L., Stein-O'Brien, G., Kagohara, L. T. & Fertig, E. J., Apr 19 2023, In: Cell Systems. 14, 4, p. 285-301.e4

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Tumor Microenvironment 100%
  • Cell Communication 60%
  • Small Cytoplasmic RNA 57%
  • Technology 41%
  • Spatial Analysis 41%
• 2022

  Chemoradiation-induced alteration of programmed death-ligand 1, CD8+ tumor-infiltrating lymphocytes and mucin expression in rectal cancer

  Baretti, M., Zhu, Q., Fu, W., Meyer, J., Wang, H., Anders, R. A. & Azad, N. S., 2022, In: Oncotarget. 13, 1, p. 907-917 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Tumor-Infiltrating Lymphocytes 100%
  • Mucins 84%
  • Chemoradiotherapy 84%
  • Rectal Neoplasms 80%
  • Ligands 55%

• Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy

  Li, K., Tandurella, J. A., Gai, J., Zhu, Q., Lim, S. J., Thomas, D. L., Xia, T., Mo, G., Mitchell, J. T., Montagne, J., Lyman, M., Danilova, L. V., Zimmerman, J. W., Kinny-Köster, B., Zhang, T., Chen, L., Blair, A. B., Heumann, T., Parkinson, R., Durham, J. N., & 11 othersNarang, A. K., Anders, R. A., Wolfgang, C. L., Laheru, D. A., He, J., Osipov, A., Thompson, E. D., Wang, H., Fertig, E. J., Jaffee, E. M. & Zheng, L., Nov 14 2022, In: Cancer cell. 40, 11, p. 1374-1391.e7

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Neoadjuvant Therapy 100%
  • Tumor Microenvironment 90%
  • Nivolumab 78%
  • Adenocarcinoma 67%
  • T-Lymphocytes 53%

• Pancreatic Ductal Adenocarcinoma Cortical Mechanics and Clinical Implications

  Angstadt, S., Zhu, Q., Jaffee, E. M., Robinson, D. N. & Anders, R. A., Jan 31 2022, In: Frontiers in Oncology. 12, 809179.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Mechanics 100%
  • Adenocarcinoma 75%
  • Neoplasms 31%
  • Cytoskeleton 23%
  • Molecular Targeted Therapy 16%
• 2021

  A feasibility study of combined epigenetic and vaccine therapy in advanced colorectal cancer with pharmacodynamic endpoint

  Bever, K. M., Thomas, D. L., Zhang, J., Diaz Rivera, E. A., Rosner, G. L., Zhu, Q., Nauroth, J. M., Christmas, B., Thompson, E. D., Anders, R. A., Judkins, C., Liu, M., Jaffee, E. M., Ahuja, N., Zheng, L. & Azad, N. S., Dec 2021, In: Clinical Epigenetics. 13, 1, 25.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • guadecitabine 100%
  • Combined Vaccines 68%
  • Active Immunotherapy 65%
  • Feasibility Studies 52%
  • Epigenomics 43%

• Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade

  Berry, S., Giraldo, N. A., Green, B. F., Cottrell, T. R., Stein, J. E., Engle, E. L., Xu, H., Ogurtsova, A., Roberts, C., Wang, D., Nguyen, P., Zhu, Q., Soto-Diaz, S., Loyola, J., Braunstein, I., Wong, P. F., Jessel, S., Doyle, J., Signer, D., Wilton, R., & 17 othersRoskes, J. S., Eminizer, M., Park, S., Sunshine, J. C., Jaffee, E. M., Baras, A., De Marzo, A. M., Topalian, S. L., Kluger, H., Cope, L., Lipson, E. J., Danilova, L., Anders, R. A., Rimm, D. L., Pardoll, D. M., Szalay, A. S. & Taube, J. M., Jun 11 2021, In: Science. 372, 6547, eaba2609.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Astronomy 100%
  • Melanoma 91%
  • Apoptosis 67%
  • Myeloid Cells 56%
  • Immunotherapy 48%

• Endothelial Stromal PD-L1 (Programmed Death Ligand 1) Modulates CD8⁺T-Cell Infiltration after Heart Transplantation

  Bracamonte-Baran, W., Gilotra, N. A., Won, T., Rodriguez, K. M., Talor, M. V., Oh, B. C., Griffin, J., Wittstein, I., Sharma, K., Skinner, J., Johns, R. A., Russell, S. D., Anders, R. A., Zhu, Q., Halushka, M. K., Brandacher, G. & Čiháková, D., Oct 1 2021, In: Circulation: Heart Failure. 14, 10, p. e007982

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Heart Transplantation 100%
  • Ligands 66%
  • T-Lymphocytes 58%
  • Transplants 35%
  • Leukocytes 22%

• Mismatch repair-deficient prostate cancer with parenchymal brain metastases treated with immune checkpoint blockade

  Sena, L. A., Salles, D. C., Engle, E. L., Zhu, Q., Tukachinsky, H., Lotan, T. L. & Antonarakis, E. S., Aug 2021, In: Cold Spring Harbor Molecular Case Studies. 7, 4

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • DNA Sequencing 100%
  • DNA Mismatch Repair 96%
  • Antitumor 74%
  • Mutation 68%
  • Prostatic Neoplasms 63%

• Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers

  Yarchoan, M., Cope, L., Ruggieri, A. N., Anders, R. A., Noonan, A. M., Goff, L. W., Goyal, L., Lacy, J., Li, D., Patel, A. K., He, A. R., Abou-Alfa, G. K., Spencer, K., Kim, E. J., Davis, S. L., McRee, A. J., Kunk, P. R., Goyal, S., Liu, Y., Dennison, L., & 9 othersXavier, S., Mohan, A. A., Zhu, Q., Wang-Gillam, A., Poklepovic, A., Chen, H. X., Sharon, E., Lesinski, G. B. & Azad, N. S., Dec 1 2021, In: Journal of Clinical Investigation. 131, 24, e152670.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • GDC-0973 100%
  • atezolizumab 87%
  • Biliary Tract Neoplasms 78%
  • Progression-Free Survival 25%
  • Antigen Presentation 20%

• Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity

  Ho, W. J., Zhu, Q., Durham, J., Popovic, A., Xavier, S., Leatherman, J., Mohan, A., Mo, G., Zhang, S., Gross, N., Charmsaz, S., Lin, D., Quong, D., Wilt, B., Kamel, I., Weiss, M. J., Philosophe, B., Burkhart, R., Burns, W. R., Shubert, C., & 11 othersEjaz, A., He, J., Deshpande, A., Danilova, L., Stein-O’Brien, G., Sugar, E. A., Laheru, D. A., Anders, R. A., Fertig, E. J., Jaffee, E. M. & Yarchoan, M., Sep 2021, In: Nature Cancer. 2, 9, p. 891-903 13 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • cabozantinib 100%
  • Nivolumab 84%
  • Immunity 50%
  • Hepatocellular Carcinoma 49%
  • Tertiary Lymphoid Structures 26%

• PD-L1 (Programmed Death Ligand 1) as a Marker of Acute Cellular Rejection after Heart Transplantation

  Choudhary, A., Brinkley, D. M., Besharati, S., Meijers, W. C., Atkinson, J. B., Amancherla, K., Zhu, Q., Huang, S., Nguyen, L. S., Salem, J. E., Ammirati, E., Lindenfeld, J., Anders, R. A. & Moslehi, J., Oct 1 2021, In: Circulation: Heart Failure. 14, 10, p. E008563

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• Phase I study of entinostat and nivolumab with or without ipilimumab in advanced solid tumors (ETCTN-9844)

  Roussos Torres, E. T., Rafie, C., Wang, C., Lim, D., Brufsky, A., LoRusso, P., Eder, J. P., Chung, V., Downs, M., Geare, M., Piekarz, R., Streicher, H., Anforth, L., Rudek, M. A., Zhu, Q., Besharati, S., Cimino-Mathews, A., Anders, R. A., Stearns, V., Jaffee, E. M., & 1 othersConnolly, R. M., Nov 15 2021, In: Clinical Cancer Research. 27, 21, p. 5828-5837 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • entinostat 100%
  • Ipilimumab 85%
  • Nivolumab 83%
  • Neoplasms 19%
  • Fatigue 11%

• Prognostic Implications of the Immune Tumor Microenvironment in Patients with Pancreatic and Gastrointestinal Neuroendocrine Tumors

  Baretti, M., Zhu, Q., Zahurak, M., Bhaijee, F., Xu, H., Engle, E. L., Kotte, A., Pawlik, T. M., Anders, R. A. & De Jesus-Acosta, A., 2021, In: Pancreas. 50, 5, p. 719-726 8 p.

  Research output: Contribution to journal › Article › peer-review

  • Neuroendocrine Tumors 100%
  • Tumor Microenvironment 91%
  • Progression-Free Survival 80%
  • Confidence Intervals 45%
  • Gastro-enteropancreatic neuroendocrine tumor 39%

• Vaccine-induced intratumoral lymphoid aggregates correlate with survival following treatment with a neoadjuvant and adjuvant vaccine in patients with resectable pancreatic adenocarcinoma

  Zheng, L., Ding, D., Edil, B. H., Judkins, C., Durham, J. N., Thomas, D. L., Bever, K. M., Mo, G., Solt, S. E., Hoare, J. A., Bhattacharya, R., Zhu, Q., Osipov, A., Onner, B., Purtell, K. A., Cai, H., Parkinson, R., Hacker-Prietz, A., Herman, J. M., Le, D. T., & 17 othersAzad, N. S., de Jesus-Acosta, A. M. C., Blair, A. B., Kim, V., Soares, K. C., Manos, L., Cameron, J. L., Makary, M. A., Weiss, M. J., Schulick, R. D., He, J., Wolfgang, C. L., Thompson, E. D., Anders, R. A., Sugar, E., Jaffee, E. M. & Laheru, D. A., Mar 1 2021, In: Clinical Cancer Research. 27, 5, p. 1278-1286 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Immunotherapy 100%
  • Adenocarcinoma 89%
  • Vaccines 85%
  • Cyclophosphamide 63%
  • Survival 62%
  2 Scopus citations
• 2020

  A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer

  Yarchoan, M., Huang, C. Y., Zhu, Q., Ferguson, A. K., Durham, J. N., Anders, R. A., Thompson, E. D., Rozich, N. S., Thomas, D. L., Nauroth, J. M., Rodriguez, C., Osipov, A., De Jesus-Acosta, A., Le, D. T., Murphy, A. G., Laheru, D., Donehower, R. C., Jaffee, E. M., Zheng, L. & Azad, N. S., Feb 1 2020, In: Cancer medicine. 9, 4, p. 1485-1494 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • GVAX vaccine 100%
  • pembrolizumab 66%
  • DNA Mismatch Repair 55%
  • Cyclophosphamide 43%
  • Colon 37%
  9 Scopus citations

• Integrated immunological analysis of a successful conversion of locally advanced hepatocellular carcinoma to resectability with neoadjuvant therapy

  Ho, W. J., Sharma, G., Zhu, Q., Stein-O'brien, G., Durham, J., Anders, R., Popovic, A., Mo, G., Kamel, I., Weiss, M., Jaffee, E., Fertig, E. J. & Yarchoan, M., Nov 20 2020, In: Journal for immunotherapy of cancer. 8, 2, e000932.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Neoadjuvant Therapy 100%
  • Hepatocellular Carcinoma 69%
  • cabozantinib 46%
  • Nivolumab 39%
  • alpha-Fetoproteins 32%
  1 Scopus citations

• Intraductal pancreatic cancer is less responsive than cancer in the stroma to neoadjuvant chemotherapy

  Fujikura, K., Hutchings, D., Braxton, A. M., Zhu, Q., Laheru, D. A., Hruban, R. H., Thompson, E. D. & Wood, L. D., Oct 1 2020, In: Modern Pathology. 33, 10, p. 2026-2034 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Pancreatic Neoplasms 100%
  • Adenocarcinoma 70%
  • Drug Therapy 62%
  • Neoplasms 34%
  • Pancreatic Ducts 17%
  1 Scopus citations
• 2019

  Abundant Expression of Lysyl Oxidase-like 2 Protein in Intrahepatic Bile Ducts of Infants with Biliary Atresia

  Honigbaum, S., Zhu, Q., Layman, A., Anders, R. A. & Schwarz, K. B., Sep 1 2019, In: Journal of pediatric gastroenterology and nutrition. 69, 3, p. 344-350 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Protein-Lysine 6-Oxidase 100%
  • Intrahepatic Bile Ducts 92%
  • Biliary Atresia 91%
  • Liver 30%
  • Staining and Labeling 25%
  1 Scopus citations

• Axon Guidance Molecules Promote Perineural Invasion and Metastasis of Orthotopic Pancreatic Tumors in Mice

  Jurcak, N. R., Rucki, A. A., Muth, S., Thompson, E., Sharma, R., Ding, D., Zhu, Q., Eshleman, J. R., Anders, R. A., Jaffee, E. M., Fujiwara, K. & Zheng, L., Sep 2019, In: Gastroenterology. 157, 3, p. 838-850.e6

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Axon Guidance 100%
  • Adenocarcinoma 57%
  • Neoplasm Metastasis 48%
  • Spinal Ganglia 31%
  • 5'-palmitoyl cytarabine 27%
  16 Scopus citations

• Correction to: persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1 (Journal for Immuno Therapy of Cancer (2019) 7 (40) DOI: 10.1186/s40425-018-0492-x)

  Smith, K. N., Llosa, N. J., Cottrell, T. R., Siegel, N., Fan, H., Suri, P., Chan, H. Y., Guo, H., Oke, T., Awan, A. H., Verde, F., Danilova, L., Anagnostou, V., Tam, A. J., Luber, B. S., Bartlett, B. R., Aulakh, L. K., Sidhom, J. W., Zhu, Q., Sears, C. L., & 21 othersCope, L., Sharfman, W. H., Thompson, E. D., Riemer, J., Marrone, K. A., Naidoo, J., Velculescu, V. E., Forde, P. M., Vogelstein, B., Kinzler, K. W., Papadopoulos, N., Durham, J. N., Wang, H., Le, D. T., Justesen, S., Taube, J. M., Diaz, L. A., Brahmer, J. R., Pardoll, D. M., Anders, R. A. & Housseau, F., Mar 6 2019, In: Journal for immunotherapy of cancer. 7, 1, 7.

  Research output: Contribution to journal › Comment/debate › peer-review

  • Consultants 100%
  • Oncogenes 88%
  • T-Lymphocytes 57%
  • Conflict of Interest 44%
  • Organized Financing 41%
  1 Scopus citations

• Evaluation of Peritumoral Fibrosis in Metastatic Colorectal Adenocarcinoma to the Liver Using Digital Image Analysis

  Waters, K. M., Cottrell, T. R., Besharati, S., Zhu, Q. & Anders, R. A., Jan 7 2019, In: American journal of clinical pathology. 151, 2, p. 226-230 5 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Adenocarcinoma 100%
  • Fibrosis 94%
  • Liver 65%
  • trichrome stain 21%
  • Biopsy 17%

• Immunopathologic stratification of colorectal cancer for checkpoint blockade immunotherapy

  Llosa, N. J., Luber, B., Siegel, N., Awan, A. H., Oke, T., Zhu, Q., Bartlett, B. R., Aulakh, L. K., Thompson, E. D., Jaffee, E. M., Durham, J. N., Sears, C. L., Le, D. T., Diaz, L. A., Pardoll, D. M., Wang, H., Housseau, F. & Anders, R. A., 2019, In: Cancer Immunology Research. 7, 10, p. 1574-1579 6 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Immunotherapy 100%
  • Colorectal Neoplasms 90%
  • Mucins 54%
  • pembrolizumab 35%
  • Microsatellite Repeats 26%
  14 Scopus citations

• Multiple immune-suppressive mechanisms in fibrolamellar carcinoma

  Kim, A. K., Gani, F., Layman, A. J., Besharati, S., Zhu, Q., Succaria, F., Engle, E. L., Bhaijee, F., Goggins, M. B., Llosa, N. J., Pawlik, T. M., Yarchoan, M., Jaffee, E. M., Simons, H. C., Taube, J. M. & Anders, R. A., May 2019, In: Cancer Immunology Research. 7, 5, p. 805-812 8 p.

  Research output: Contribution to journal › Article › peer-review

  • Carcinoma 100%
  • Neoplasms 42%
  • Tumor-Infiltrating Lymphocytes 23%
  • Cytotoxic T-Lymphocytes 20%
  • Myeloid Cells 19%
  6 Scopus citations

• Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1

  Smith, K. N., Llosa, N. J., Cottrell, T. R., Siegel, N., Fan, H., Suri, P., Chan, H. Y., Guo, H., Oke, T., Awan, A. H., Verde, F., Danilova, L., Anagnostou, V., Tam, A. J., Luber, B. S., Bartlett, B. R., Aulakh, L. K., Sidhom, J. W., Zhu, Q., Sears, C. L., & 21 othersCope, L., Sharfman, W. H., Thompson, E. D., Riemer, J., Marrone, K. A., Naidoo, J., Velculescu, V. E., Forde, P. M., Vogelstein, B., Kinzler, K. W., Papadopoulos, N., Durham, J. N., Wang, H., Le, D. T., Justesen, S., Taube, J. M., Diaz, L. A., Brahmer, J. R., Pardoll, D. M., Anders, R. A. & Housseau, F., Feb 11 2019, In: Journal for immunotherapy of cancer. 7, 1, 40.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Oncogenes 100%
  • T-Lymphocytes 65%
  • Turcot syndrome 62%
  • Biomarkers 54%
  • DNA Mismatch Repair 50%
  17 Scopus citations

• Programmed cell death ligand-1 (PD-L1) and CD8 expression profiling identify an immunologic subtype of pancreatic ductal adenocarcinomas with favorable survival

  Danilova, L., Ho, W. J., Zhu, Q., Vithayathil, T., De Jesus-Acosta, A., Azad, N. S., Laheru, D. A., Fertig, E. J., Anders, R., Jaffee, E. M. & Yarchoan, M., Jun 2019, In: Cancer Immunology Research. 7, 6, p. 886-895 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Adenocarcinoma 100%
  • Ligands 90%
  • Apoptosis 77%
  • Survival 70%
  • Biomarkers 27%
  28 Scopus citations

• Quantitative characterization of CD8+ T cell clustering and spatial heterogeneity in solid tumors

  Gong, C., Anders, R. A., Zhu, Q., Taube, J. M., Green, B., Cheng, W., Bartelink, I. H., Vicini, P., Wang, B. & Popel, A. S., 2019, In: Frontiers in Oncology. 9, JAN, 649.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Cluster Analysis 100%
  • Tumor Microenvironment 77%
  • T-Lymphocytes 69%
  • Systems Biology 44%
  • Workflow 41%
  11 Scopus citations

• Targeting mechanoresponsive proteins in pancreatic cancer: 4-hydroxyacetophenone blocks dissemination and invasion by activating MYH14

  Surcel, A., Schiffhauer, E. S., Thomas, D. G., Zhu, Q., DiNapoli, K. T., Herbig, M., Otto, O., West-Foyle, H., Jacobi, A., Krater, M., Plak, K., Guck, J., Jaffee, E. M., Iglesias, P. A., Anders, R. A. & Robinson, D. N., Sep 15 2019, In: Cancer Research. 79, 18, p. 4665-4678 14 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • 4-hydroxyacetophenone 100%
  • Pancreatic Neoplasms 48%
  • Filamins 25%
  • Actinin 23%
  • Proteins 18%
  13 Scopus citations

• Transient c-Src Suppression During Endodermal Commitment of Human Induced Pluripotent Stem Cells Results in Abnormal Profibrotic Cholangiocyte-Like Cells

  Chaudhari, P., Tian, L., Kim, A., Zhu, Q., Anders, R., Schwarz, K. B., Sharkis, S., Ye, Z. & Jang, Y. Y., Mar 2019, In: Stem Cells. 37, 3, p. 306-317 12 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Induced Pluripotent Stem Cells 100%
  • Human Development 47%
  • Liver 45%
  • Fibrosis 43%
  • Protein-Tyrosine Kinases 26%
  5 Scopus citations
• 2018

  Histopathological and immunophenotypic features of ipilimumab-associated colitis compared to ulcerative colitis

  Adler, B. L., Pezhouh, M. K., Kim, A., Luan, L., Zhu, Q., Gani, F., Yarchoan, M., Chen, J., Voltaggio, L., Parian, A., Lazarev, M., Lauwers, G. Y., Pawlik, T. M., Montgomery, E. A., Jaffee, E., Le, D. T., Taube, J. M. & Anders, R. A., Jun 2018, In: Journal of Internal Medicine. 283, 6, p. 568-577 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Ipilimumab 100%
  • Colitis 73%
  • Ulcerative Colitis 70%
  • Biopsy 6%
  • Extracellular Vesicles 6%
  15 Scopus citations
• 2017

  Characterization of the immune microenvironment in hepatocellular carcinoma

  Yarchoan, M., Xing, D., Luan, L., Xu, H., Sharma, R. B., Popovic, A., Pawlik, T. M., Kim, A. K., Zhu, Q., Jaffee, E. M., Taube, J. M. & Anders, R. A., Dec 1 2017, In: Clinical Cancer Research. 23, 23, p. 7333-7339 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Hepatocellular Carcinoma 100%
  • Neoplasms 40%
  • Liver 38%
  • CD8-Positive T-Lymphocytes 36%
  • Tumor-Infiltrating Lymphocytes 31%
  49 Scopus citations

• HOXB7 promotes tumor progression via bFGF-induced activation of MAPK/ERK pathway and indicated poor prognosis in hepatocellular carcinoma

  Wang, W. M., Xu, Y., Wang, Y. H., Sun, H. X., Sun, Y. F., He, Y. F., Zhu, Q. F., Hu, B., Zhang, X., Xia, J. L., Qiu, S. J., Zhou, J., Yang, X. R. & Fan, J., 2017, In: Oncotarget. 8, 29, p. 47121-47135 15 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • MAP Kinase Signaling System 100%
  • Fibroblast Growth Factor 2 97%
  • Hepatocellular Carcinoma 73%
  • Recurrence 29%
  • Neoplasms 29%
  19 Scopus citations
• 2016

  Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma

  Gani, F., Nagarajan, N., Kim, Y., Zhu, Q., Luan, L., Bhaijjee, F., Anders, R. A. & Pawlik, T. M., Aug 1 2016, In: Annals of surgical oncology. 23, 8, p. 2610-2617 8 p.

  Research output: Contribution to journal › Article › peer-review

  • Cholangiocarcinoma 100%
  • Tumor Microenvironment 89%
  • Neoplasms 27%
  • Macrophages 11%
  • Survival 6%
  73 Scopus citations

• Yes-associated protein impacts adherens junction assembly through regulating actin cytoskeleton organization

  Bai, H., Zhu, Q., Surcel, A., Luo, T., Ren, Y., Guan, B., Liu, Y., Wu, N., Joseph, N. E., Wang, T. L., Zhang, N., Pan, D., Alpini, G., Robinson, D. N. & Anders, R. A., 2016, In: American Journal of Physiology - Gastrointestinal and Liver Physiology. 311, 3, p. G396-G411

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Adherens Junctions 100%
  • Actin Cytoskeleton 76%
  • Actomyosin 40%
  • Elasticity 34%
  • Jaundice 32%
  23 Scopus citations
• 2015

  A polymeric nanoparticle formulation of curcumin in combination with sorafenib synergistically inhibits tumor growth and metastasis in an orthotopic model of human hepatocellular carcinoma

  Hu, B., Sun, D., Sun, C., Sun, Y. F., Sun, H. X., Zhu, Q. F., Yang, X. R., Gao, Y. B., Tang, W. G., Fan, J., Maitra, A., Anders, R. A. & Xu, Y., Dec 25 2015, In: Biochemical and Biophysical Research Communications. 468, 4, p. 525-532 8 p.

  Research output: Contribution to journal › Article › peer-review

  • Sorafenib 100%
  • Curcumin 73%
  • Nanoparticles 56%
  • Hepatocellular Carcinoma 51%
  • Neoplasm Metastasis 39%
  36 Scopus citations

• Pharmacological activation of myosin ii paralogs to correct cell mechanics defects

  Surcel, A., Ng, W. P., West-Foyle, H., Zhu, Q., Ren, Y., Avery, L. B., Krenc, A. K., Meyers, D. J., Rock, R. S., Anders, R. A., Meyers, C. L. F. & Robinson, D. N., Feb 3 2015, In: Proceedings of the National Academy of Sciences of the United States of America. 112, 5, p. 1428-1433 6 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • 4-hydroxyacetophenone 100%
  • Myosins 98%
  • Mechanics 93%
  • Pharmacology 59%
  • Myosin Type II 52%
  33 Scopus citations
• 2014

  The use of Yes-associated protein expression in the diagnosis of persistent neonatal cholestatic liver disease

  Gurda, G. T., Zhu, Q., Bai, H., Pan, D., Schwarz, K. B. & Anders, R. A., May 2014, In: Human pathology. 45, 5, p. 1057-1064 8 p.

  Research output: Contribution to journal › Article › peer-review

  • Biliary Atresia 100%
  • Liver Diseases 72%
  • Cholestasis 61%
  • Bile Ducts 33%
  • Proteins 31%
  19 Scopus citations
• 2013

  Hypoxia inducible factor 2 alpha inhibits hepatocellular carcinoma growth through the transcription factor dimerization partner 3/E2F transcription factor 1-dependent apoptotic pathway

  Sun, H. X., Xu, Y., Yang, X. R., Wang, W. M., Bai, H., Shi, R. Y., Nayar, S. K., Devbhandari, R. P., He, Y. Z., Zhu, Q. F., Sun, Y. F., Hu, B., Khan, M., Anders, R. A. & Fan, J., Mar 2013, In: Hepatology. 57, 3, p. 1088-1097 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • endothelial PAS domain-containing protein 1 100%
  • E2F1 Transcription Factor 96%
  • Dimerization 70%
  • Hepatocellular Carcinoma 49%
  • Transcription Factors 46%
  54 Scopus citations
• 2012

  Polymeric nanoparticle-encapsulated hedgehog pathway inhibitor HPI-1 (NanoHHI) inhibits systemic metastases in an orthotopic model of human hepatocellular carcinoma

  Xu, Y., Chenna, V., Hu, C., Sun, H. X., Khan, M., Bai, H., Yang, X. R., Zhu, Q. F., Sun, Y. F., Maitra, A., Fan, J. & Anders, R. A., Mar 1 2012, In: Clinical Cancer Research. 18, 5, p. 1291-1302 12 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Nanoparticles 100%
  • Hepatocellular Carcinoma 90%
  • Neoplasm Metastasis 69%
  • Sorafenib 21%
  • Recurrence 19%
  51 Scopus citations

• The role of the TOB1 gene in growth suppression of hepatocellular carcinoma

  Lin, S., Zhu, Q., Xu, Y., Liu, H., Zhang, J., Xu, J., Wang, H., Sang, Q., Xing, Q. & Fan, J., Nov 2012, In: Oncology Letters. 4, 5, p. 981-987 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Hepatocellular Carcinoma 100%
  • Methylation 64%
  • Growth 62%
  • Genes 49%
  • Liver Neoplasms 35%
  5 Scopus citations
• 2011

  The role of polymeric immunoglobulin receptor in inflammation-induced tumor metastasis of human hepatocellular carcinoma

  Ai, J., Tang, Q., Wu, Y., Xu, Y., Feng, T., Zhou, R., Chen, Y., Gao, X., Zhu, Q., Yue, X., Pan, Q., Xu, S., Li, J., Huang, M., Daugherty-Holtrop, J., He, Y., Xu, H. E., Fan, J., Ding, J. & Geng, M., Nov 16 2011, In: Journal of the National Cancer Institute. 103, 22, p. 1696-1712 17 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Polymeric Immunoglobulin Receptors 100%
  • Hepatocellular Carcinoma 49%
  • Neoplasm Metastasis 38%
  • Inflammation 36%
  • Neoplasms 20%
  46 Scopus citations